Corium Intl Cmn (CORI) 4.72 $CORI Corium to Report Third

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Corium Intl Cmn (CORI) 4.72 $CORI

Corium to Report Third Quarter Fiscal Year 2016 Financial Results on Thursday, August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third fiscal quarter ended June 30, 2016 on Thursday, August 4, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 4.72 (-0.06)

Corium Presents Full Clinical Results from Phase 1 Pharmacokinetic Study of Once-weekly Corplex(TM) Donepezil Transdermal System
GlobeNewswire - Wed Jul 27, 3:01PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the presentation of full clinical trial results demonstrating sustained and controlled delivery of donepezil in the plasma concentrations of all subjects treated with Corium's once-weekly Corplex Donepezil patch. Consistent with topline interim data, the average plasma concentration with Corplex Donepezil was comparable to oral Aricept (donepezil hydrochloride), and indicative of bioequivalence. These pharmacokinetic results enabled Corium to select an optimized formulation for further clinical development and support an expedited development pathway for Corplex Donepezil.
CORI: 4.72 (-0.06)

Can The Uptrend Continue for Corium International (CORI)?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:57AM CDT
Investors certainly have to be happy with Corium International Inc (CORI) and its short term performance
CORI: 4.72 (-0.06)

Corium to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed May 25, 3:05PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 1:30 p.m. Eastern time.
CORI: 4.72 (-0.06)

Corium reports 2Q loss
Automated Insights - Tue May 10, 5:06PM CDT
MENLO PARK, Calif. (AP) _ Corium International Inc. (CORI) on Tuesday reported a loss of $10.5 million in its fiscal second quarter.
CORI: 4.72 (-0.06)

Corium Reports Second Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
GlobeNewswire - Tue May 10, 4:07PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal quarter and the six months ended March 31, 2016 and reported on recent corporate developments. Corium's fiscal year ends on September 30.
CORI: 4.72 (-0.06)

Corium International (CORI) Jumps: Stock Moves 9.5% Higher
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:15AM CDT
Corium International, Inc. (CORI) shares rose almost 10% in the last trading session.
CORI: 4.72 (-0.06), AMPH: 16.28 (+0.10)

Corium to Report Second Quarter Fiscal Year 2016 Financial Results on Tuesday, May 10, 2016
GlobeNewswire - Tue May 03, 3:06PM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second fiscal quarter ended March 31, 2016 on Tuesday, May 10, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 4.72 (-0.06)

Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex(TM) Donepezil Following Positive Pre-IND Communication from FDA
GlobeNewswire - Mon May 02, 3:05PM CDT
Reports Positive PK Results from Clinical Study of Optimized Once-weekly Corplex Donepezil for Alzheimer's Disease
CORI: 4.72 (-0.06)

Docutech(TM) announces David Aach to join as New Executive Vice President
BusinessWire - Thu Mar 31, 8:00AM CDT
Docutech, a leading provider of compliance and documentation technology, today announced that David Aach has joined the management team. In his role, Aach will initially focus on helping to grow revenues by working closely with Docutech's industry partners and financial services clients and prospects.
CORI: 4.72 (-0.06), IBM: 160.92 (+0.30)

Corium to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Mar 31, 7:00AM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time.
CORI: 4.72 (-0.06)

Corium Announces Positive Preclinical Results with Long-acting Potent GLP-1 Analog Delivered in MicroCor(R) Transdermal Patch
GlobeNewswire - Tue Mar 29, 3:03PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the publication of a paper in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS), titled "Long-acting Potent GLP-1 Analog Delivered in Microstructure-based Transdermal Patch". The results demonstrate that the combination of MicroCor transdermal system with E6, a new GLP-1R agonist, resulted in improved peptide effectiveness by increasing plasma stability and providing sustained glucose control in a preclinical proof-of-concept study.
CORI: 4.72 (-0.06)

Corium incurs higher net loss of USD9.4m for Q1 fiscal 2016
M2 - Tue Feb 09, 3:59AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) on Monday declared a net loss of USD9.4m (USD0.42 per share) for the first fiscal quarter ended 31 December 2015.
CORI: 4.72 (-0.06)

Corium Reports First Quarter Fiscal 2016 Financial Results
GlobeNewswire - Mon Feb 08, 3:03PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended December 31, 2015. Corium's fiscal year ends on September 30.
CORI: 4.72 (-0.06)

Corium International (CORI) Jumps: Stock Moves Up 8.9%
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 7:15AM CST
Corium International, Inc. (CORI) shares rise almost 9% in the last trading session.
MNK: 66.55 (-0.79), CORI: 4.72 (-0.06)

Corium Announces Positive Topline Results From Phase 1 PK Clinical Study of Once-Weekly Transdermal Corplex(TM) Donepezil as a Potential Treatment of Alzheimer's Disease
GlobeNewswire - Wed Feb 03, 3:03PM CST
Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-Weekly Dosing
CORI: 4.72 (-0.06)

Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.39 (-0.16), TRVN: 6.33 (+0.06), VRTX: 97.49 (+0.49), RDHL: 14.44 (+1.31), ZSAN: 1.62 (-0.13), AMGN: 173.88 (+1.85), LLY: 83.19 (+0.30), ACOR: 25.41 (+0.13), NKTR: 17.68 (+0.39), AGN: 253.86 (+0.91), CORI: 4.72 (-0.06), ALDR: 31.09 (-1.01), CLCD: 8.89 (+0.19), MRK: 58.65 (-0.01), TEVA: 53.54 (+0.04), RVNC: 13.20 (-0.29), POZN: 5.94 (-0.43)

Corium to Present at LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Tue Jan 26, 7:01AM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the LEERINK Partners 5 Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. Eastern time.
CORI: 4.72 (-0.06)

Equities on the Move - Research on Xerium, Mattersight, Corium International and Sears Hometown
ACCESSWIRE - Mon Nov 30, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Xerium Technologies Inc. (NYSE: XRM), Mattersight Corp. (NASDAQ: MATR), Corium International Inc. (NASDAQ: CORI) and Sears Hometown and Outlet Stores Inc. (NASDAQ: SHOS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CORI: 4.72 (-0.06), MATR: 4.44 (+0.11), XRM: 7.47 (+0.02), SHOS: 6.75 (-0.13)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin’s Price Dynamics: Labor Reports and Elections Impacting Trends

Updated Category News Views 197

Labor Market Reports and Bitcoin's Future Into The Cryptoverse founder Benjamin Cowen shares insights on the current trajectory of Bitcoin as market dynamics shift with upcoming labor market reports and election results. Market Predictions Impacted by External Factors Cowen emphasizes that predictions in the short term remain complex. He notes that the momentum of the...

Continue Reading
Wearable Materials Market Forecast: Growth to USD 9.14 Billion

Updated Category News Views 238

Overview of the Wearable Materials Market The Wearable Materials Market is on an impressive trajectory, with an anticipated growth from USD 3.24 billion in 2024 to USD 9.14 billion by 2032. This surge represents a compounded annual growth rate (CAGR) of 13.85% during the forecast years. Such expansion is astonished by the increasing demand for wearables associated with...

Continue Reading
Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 382

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Exploring the Rapid Growth of the Virtual Cards Market

Updated Category News Views 154

Overview of the Virtual Cards Market The global virtual cards market is poised for substantial growth, with estimates suggesting an increase of USD 428.6 billion from 2025 to 2029. A significant annual growth rate of 17.1% during this period is projected, reflecting the ongoing transformations in the payment landscape, particularly driven by advancements in technology and...

Continue Reading
Appian Introduces Advanced AI Features to Revolutionize Workflow

Updated Category News Views 240

Transforming Business Processes with AI Appian, renowned for its innovative process automation solutions, has just rolled out significant enhancements to its platform. By embedding sophisticated AI agents into enterprise workflows, Appian is making strides in automating complex tasks, and empowering business users to revamp outdated applications seamlessly. Empowering...

Continue Reading